A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

NCT00697060 | Withdrawn Phase 2

• 1 other identifier: AMP024
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 3

Brief Summary

Protocol AMP-024 is a Phase 2 study of imexon plus docetaxel for patients with previously treated lung cancer that has spread in the body. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for this cancer. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is to determine if the combination of imexon plus docetaxel is safe and effective.

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

Metastatic; Previously treated

Outcome Measures

Primary Outcomes (1)

• Overall response rates (CR + PR) in subjects with measurable disease will be determined by RECIST methodology.

  every 6 weeks

Secondary Outcomes (6)

• Progression-free survival (PFS), as measured from the date of registration to the date of recorded disease progression (PD) or death from any cause.

  throughout the study

• Overall survival, as measured from the date of registration to the date of death from any cause.

  throughout the study

• Stable disease rate at 2 months.

  2 months

• Survival at 1-year.

  1 year

• Duration of response and stable disease.

  throughout the study

Study Arms (1)

Stage 1/2

EXPERIMENTAL

Imexon plus docetaxel

Drug: Imexon + docetaxel

Interventions

Imexon + docetaxel DRUG

Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1

Also known as: Amplimexon, Taxotere

Stage 1/2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with histologically or cytologically confirmed NSCLC.
• Subject with metastatic disease (Appendix D) who have received no more than 2 prior chemotherapy regimens for their metastatic disease.
• Adjuvant chemotherapy is considered one prior regimen.
• Immunological and targeted agents such as bevacizumab, erlotinib or gefitinib are considered prior regimens.
• Subjects must have at least one measurable lesion by RECIST criteria (Appendix C). If the only measurable lesion is a lymph node, it must measure at least 20 mm in LD, and if the only target lesion is a single lesion, a cytological or histological confirmation of NSCLC is required.
• Resolution of all chemotherapy or radiotherapy-related toxicities to CTCAE grade 1 or lower, except for stable sensory neuropathy of \< grade 2 and/or alopecia.
• Men and women age \> 18 years.
• ECOG performance status of 0 - 1 (Appendix E).
• Not pregnant nor lactating.
• If of child bearing potential must be able and agree to use adequate contraception.
• Adequate renal function defined by:
• serum creatinine level \< 2.0 mg/dL.
• G6PD (quantitative) greater than or equal to the lower limit of normal.
• Adequate hematologic function defined by:
• absolute neutrophil count (ANC) \>1,500/mm³, and

You may not qualify if:

• Subjects who have received previous treatment with docetaxel.
• Subjects who have received chemotherapy or radiation treatments within 4 weeks of study treatment start.
• Prior high dose chemotherapy with hematopoietic stem cell rescue within the past two years.
• Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen and/or the medical management of recurrent pleural effusions.
• Subjects with meningeal carcinomatosis.
• Women who are pregnant or breast-feeding, women of child bearing potential (WOCBP) with either a positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) or no pregnancy test; WOCBP unless (1) surgically sterile (hysterectomy, or bilateral oophorectomy) or (2) not using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
• Severe or uncontrolled intercurrent infection or other illness.
• Significant cardiovascular disease including but not limited to a history of congestive heart failure of \> NYHA grade II (Appendix E), unstable angina or a myocardial infarction within the past six months, or serious and uncontrolled arrhythmia.
• Subjects with organ allografts.
• Subjects who have had a prior malignancy, other than carcinoma in situ of the cervix, non-melanoma skin cancer, and superficial bladder cancer unless the prior malignancy was diagnosed and definitively treated \> 5 years previously with no subsequent evidence of recurrence.
• Subjects with pre-existing neuropathy \> CTCAE Grade 2.
• Subjects with other significant disease or disorders that, in the opinion of the Investigator, would exclude the subject from the study

Sponsors & Collaborators

• AmpliMed Corporation: lead

Study Sites (3)

USC Norris Cotton Cancer Center

Los Angeles, California, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, United States

Location

Mary Crowley Research Center

Dallas, Texas, United States

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis

Interventions

4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one; Docetaxel

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Evan Hersh, MD

  AmpliMed Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 11, 2008
• First Posted: June 13, 2008
• Study Start: August 1, 2010
• Primary Completion: August 1, 2011
• Study Completion: August 1, 2012
• Last Updated: June 24, 2015

Record last verified: 2015-06

Locations

US (3)